Evolving Therapeutic Strategies in Esophageal Squamous Cell Carcinoma: Advances and Perspectives Authors: Zhibin Liu, Myoung Ok Kim Published: 2024 ABSTRACT Esophageal squamous cell carcinoma (ESCC) is among the most prevalent forms of esophageal cancer globally, with a particularly high incidence in developing countries. Notably, Asia accounts for approximately 80% of global esophageal cancer cases, with China alone contributing to 54% of this burden. The primary treatment modality for ESCC remains esophagectomy, primarily employed for locally advanced disease, often in combination with chemotherapy and radiotherapy for advanced-stage cases. Despite significant advancements in surgical techniques and the advent of precision medicine, which has facilitated the development of targeted and immune-based therapies, critical challenges persist, including suboptimal therapeutic efficacy and the emergence of drug resistance. A comprehensive understanding of the current treatment landscape for ESCC is essential to overcoming these barriers and improving patient outcomes. INTRODUCTION Esophageal cancer is generally classified into two main histological subtypes: esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) [1]. ESCC is the predominant type globally, particularly in developing countries, whereas EAC is more prevalent in developed nations, with a significant incidence in Western populations [2]. The rising incidence of EAC has been strongly associated with gastroesophageal reflux disease, Barrett’s esophagus, obesity, and chronic acid exposure [3]. ESCC is among the most prevalent forms of esophageal cancer worldwide, particularly in developing countries [4]. Notably, Asia accounts for 80% of global cases, with China contributing 54%, underscoring the substantial patient burden in this region [5]. Clinical manifestations, including dysphagia, chest pain, retrosternal burning, weight loss, fatigue, and bleeding, pose significant challenges to treatment and complicate post-surgical recovery. Despite advancements in surgical techniques and the development of diverse therapeutic strategies, esophageal cancer remains one of the most difficult malignancies to treat effectively [6,7]. Adjuvant chemotherapy and radiotherapy are commonly employed in advanced cases [8,9]. Furthermore, lifestyle-related factors such as smoking, alcohol consumption, malnutrition, anemia, and chronic inflammation have been identified as major risk factors for ESCC, contributing to its rising incidence in recent years [10-13]. This review provides a discussion of the roles and efficacy of surgical, chemotherapeutic, and radiotherapeutic approaches in the management of ESCC, with reference to the most recent studies. ESOPHAGECTOMY Esophagectomy remains the most reliable curative option for early-stage, locally advanced, and non-metastatic ESCC. Common surgical approaches include traditional open surgery and minimally invasive techniques. Traditional open surgery: techniques such as the Ivor-Lewis procedure and three-incision esophagectomy, involving cervical, thoracic, and abdominal incisions, are particularly suited for early and locally advanced cases [14,15]. Minimally invasive esophagectomy (MIE): this emerging approach utilizes thoracoscopic or laparoscopic techniques and is recommended for patients in good physical condition without extensive tumor invasion [16-18]. Endoscopic therapy: endoscopic mucosal resection and endoscopic submucosal dissection are preferred for early-stage lesions [19,20]. Lymphadenectomy is an integral component of esophagectomy, with notable geographical variations in practice. Western surgeons generally perform two-field lymphadenectomy, whereas three-field dissection is advocated by many Asian surgeons, particularly in Japan, for SCC [21,22]. Although debates persist regarding its associated risks and benefits, esophagectomy remains the gold standard for surgical management of ESCC [23]. An overview of the historical evolution of surgical approaches for esophageal cancer, along with their respective advantages and limitations, is presented in Figure 1 and Table 1. These findings provide a valuable framework for evaluating the progression of treatment strategies and guiding future clinical decision-making [24-28]. CHEMOTHERAPY AND RADIATION THERAPY Chemotherapy and radiotherapy are well-established standard treatment modalities for the majority of cancers [29-31]. Specifically, for advanced ESCC, these therapies serve as essential components of treatment, often employed as adjuvant therapies following esophagectomy to mitigate the risks of recurrence and metastasis. Furthermore, for patients deemed ineligible for surgical intervention, chemotherapy and radiotherapy remain the primary therapeutic options [32]. Chemotherapeutic regimens for advanced or metastatic ESCC commonly include combinations such as cisplatin with 5-FU, paclitaxel, or docetaxel, which have been shown to prolong survival and enhance the efficacy of radiotherapy [33]. Despite these benefits, chemotherapy is limited by considerable systemic toxicities, including nausea, vomiting, alopecia, and the development of drug resistance (Table 2) [34-36]. Radiotherapy, utilizing advanced techniques such as three-dimensional conformal radiotherapy [37,38], intensity-modulated radiotherapy (IMRT) [39-41], and proton therapy, offers targeted treatment with varying levels of precision [42,43]. It is particularly effective in cases where surgery is not feasible or for addressing post-surgical residual disease. However, radiotherapy is associated with significant adverse effects, including radiation-induced esophagitis and pneumonitis (Table 3) [44-46]. Emerging evidence indicates that neoadjuvant chemoradiotherapy is highly effective for managing locally advanced ESCC [47,48]. Nonetheless, salvage esophagectomy, performed to treat residual or recurrent disease following chemoradiotherapy, carries a high risk of morbidity and mortality [32,43,49]. This underscores the importance of meticulous patient selection to optimize outcomes. DISCUSSION ESCC continues to present significant challenges in clinical management, particularly in regions with high incidence rates, such as Asia [50]. Despite advances in surgical techniques, chemotherapy, and radiotherapy, ESCC remains a highly aggressive cancer, with late-stage diagnoses contributing to high mortality rates [51]. One promising development in surgery is MIE, which has been shown to reduce postoperative complications and promote faster recovery compared to traditional open surgery [52,53]. However, the widespread adoption of MIE has been slow due to technical challenges and the steep learning curve associated with thoracoscopic and laparoscopic techniques. Long-term survival benefits of MIE, especially for locally advanced cases, are still under investigation, but it has already established itself as the preferred surgical option for early-stage tumors in well-selected patients [54]. Chemotherapy and radiotherapy are crucial components of ESCC treatment, especially for advanced cases [55,56]. Common chemotherapy regimens, such as cisplatin combined with 5-FU, paclitaxel, or docetaxel, have been shown to improve survival rates, particularly when combined with radiotherapy. However, these regimens are often accompanied by considerable systemic toxicities, including nausea, vomiting, alopecia, and drug resistance [57,58]. Innovations in radiotherapy, such as IMRT and proton therapy, have improved treatment precision, reducing damage to healthy tissues and minimizing side effects like radiation-induced esophagitis and pneumonitis [59]. Neoadjuvant chemoradiotherapy has emerged as an effective treatment for locally advanced ESCC, with evidence suggesting it can reduce tumor size and improve surgical outcomes [60,61]. However, salvage esophagectomy after neoadjuvant therapy remains a high-risk procedure, necessitating careful patient selection and monitoring. Looking ahead, the development of personalized therapies based on molecular profiling and the use of targeted therapies and immunotherapies, such as immune checkpoint inhibitors, offer potential breakthroughs in improving treatment outcomes, particularly for metastatic ESCC. These advancements could revolutionize ESCC treatment, providing new hope for patients with limited options. CONCLUSION In conclusion, treatment strategies for ESCC, as with other cancers, are tailored to the stage of the disease and the tumor’s characteristics. MIE has emerged as the preferred approach for early-stage ESCC, offering effective tumor resection with reduced invasiveness and minimized injury to surrounding tissues. In cases of advanced ESCC, chemotherapy and radiotherapy serve as critical components, either as adjuvant therapies or as standalone treatment modalities. Additionally, neoadjuvant and salvage therapies expand the range of options available, though their risks and benefits require careful consideration. Continued advancements in research and the development of precision medicine are expected to further enhance and individualize the management of ESCC.